The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent
does not generally provide durable glycaemic control over the long term. Sulphonylurea …

Liraglutide is an acylated glucagon-like peptide-1 analogue with 97% amino acid homology
with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the …

Dulaglutide (DU) is a once weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)
approved for the treatment of type 2 diabetes mellitus (T2DM). Glycaemic efficacy and safety …

Insulin treatment of individuals with type 1 diabetes has shortcomings and many patients do
not achieve glycaemic and metabolic targets. Consequently, the focus is on novel non …

Background & Aims Hyperglycemia is implicated as a major risk factor for delayed gastric
emptying in diabetes mellitus and vice versa. However, the extent to which hyperglycemia …

GLP-1 and its based drugs possess extrapancreatic metabolic functions, including that in the
liver. These direct hepatic metabolic functions explain their therapeutic efficiency for subjects …

Background Beneficial roles for glucagon-like peptide 1 (GLP-1)/GLP-1R signaling have
recently been described in diseases, where low-grade inflammation is a common …

Regulatory peptides produced in islet and gut endocrine cells, including glucagon, glucagon-
like peptide-1 (GLP-1), GLP-2, and glucose-dependent insulinotropic polypeptide, exert …

Type 2 diabetes is a rapidly growing disease that poses a significant burden to the United
States healthcare system. Despite the many available treatments for the disease, close to …